CB801

CB801 is an early-stage therapeutic candidate being developed by Cascade Biotechnology for the treatment of Alzheimer's disease. The drug is based on Cascade's proprietary sC3 (soluble Complement 3) platform, which utilizes complement-depleting proteins to modulate the immune response. By targeting the complement system, CB801 aims to address neuroinflammation and pathological synaptic pruning, which are thought to contribute to the progression of Alzheimer's disease. As of early 2024, the program is in the preclinical stage, specifically undergoing in vitro research to evaluate its efficacy in depleting complement components and reducing neurotoxic inflammatory processes.